News Related to Objective Response

Related coverage linked through entity extraction aliases.

Early ctDNA Changes Predict Survival in Advanced Melanoma Treated With Immunotherapy

Mar 13, 2026

Decreases in circulating tumor DNA within 3-4 weeks of immune checkpoint inhibitor therapy were strongly associated with higher response rates and longer survival in patients with unresectable stage III/IV melanoma, according to a multi-institutional retrospective analysis.

FDA Expedites Review of Daraxonrasib for Pancreatic Cancer Treatment

Mar 12, 2026

The FDA is accelerating its review of daraxonrasib, a targeted therapy for pancreatic cancer, under a new pilot program that could reduce approval time from 10-12 months to one to two months.